A pathway from leukemogenic oncogenes and stem cell chemokines to RNA processing via THOC5

Leukemia

Volumn 27, Issue 4, 2013, Pages 932-940

  Griaud, F ^a   Pierce, A ^a   Gonzalez Sanchez, M B ^a   Scott, M ^b   Abraham, S A ^b   Holyoake, T L ^b   Tran, D D H ^c   Tamura, T ^c   Whetton, A D ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

CML; motility; mRNA export complex THOC

Indexed keywords

CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; PROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; THOC5 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; LEUKEMIA; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA PROCESSING;

CHEMOKINES; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA; NUCLEAR PROTEINS; ONCOGENES; PHOSPHORYLATION; RNA PROCESSING, POST-TRANSCRIPTIONAL; SIGNAL TRANSDUCTION; STEM CELLS; TYROSINE;

EID: 84876144115     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.283     Document Type: Article

References (41)

1. Reed R, Cheng H. TREX, SR proteins and export of mRNA. Curr Opin Cell Biol 2005; 17: 269-273.
2. Rehwinkel J, Herold A, Gari K, Kocher T, Rode M, Ciccarelli FL et al. Genome-wide analysis of mRNAs regulated by the THO complex in Drosophila melanogaster. Nat Struct Mol Biol 2004; 11: 558-566.
3. Gallardo M, Luna R, Erdjument-Bromage H, Tempst P, Aguilera A. Nab2p and the Thp1p-Sac3p complex functionally interact at the interface between transcription and mRNA metabolism. J Biol Chem 2003; 278: 24225-24232.
4. Guria A, Tran DDH, Ramachandran S, Koch A, El Bounkari O, Dutta P et al. Identification of mRNAs that are spliced but not exported to the cytoplasm in the absence of THOC5 in mouse embryo fibroblasts. RNA-A Publication of the RNA Society 2011; 17: 1048-1056.
5. Katahira J, Inoue H, Hurt E, Yoneda Y. Adaptor Aly and co-adaptor Thoc5 function in the Tap-p15-mediated nuclear export of HSP70 mRNA. EMBO J 2009; 28: 556-567.
6. Mancini A, El Bounkari O, Norrenbrock AF, Scherr M, Schaefer D, Eder M et al. FMIP controls the adipocyte lineage commitment of C2C12 cells by downmodulation of C//EBPalpha. Oncogene 2007; 26: 1020-1027.
7. Tamura T, Mancini A, Joos H, Koch A, Hakim C, Dumanski J et al. FMIP, a novel Fms-interacting protein, affects granulocyte/macrophage differentiation. Oncogene 1999; 18: 6488-6495.
8. Pierce A, Carney L, Hamza HG, Griffiths JR, Zhang L, Whetton BA et al. THOC5 spliceosome protein: a target for leukaemogenic tyrosine kinases that affects inositol lipid turnover. Br J Haematol 2008; 141: 641-650.
9. Mancini A, Niemann-Seyde SC, Pankow R, El Bounkari O, Klebba-Faerber S, Koch A et al. THOC5/FMIP, an mRNA export TREX complex protein, is essential for hematopoietic primitive cell survival in vivo. BMC Biol 2010; 8: 1.
10. Ito K, Hirao A, Arai F, Matsuoka S, Takubo K, Hamaguchi I et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 2004; 431: 997-1002.
11. Mancini A, Koch A, Whetton AD, Tamura T. The M-CSF receptor substrate and interacting protein FMIP is governed in its subcellular localization by protein kinase C-mediated phosphorylation, and thereby potentiates M-CSF-mediated differentiation. Oncogene 2004; 23: 6581-6589.
12. Pierce A, Whetton AD, Owen-Lynch PJ, Tavernier J, Spooncer E, Dexter TM et al. Ectopic interleukin-5 receptor expression promotes proliferation without development in a multipotent hematopoietic cell line. J Cell Sci 1998; 111: 815-823.
13. Pierce A, Williamson A, Jaworska E, Griffiths JR, Taylor S, Walker M et al. Identification of nuclear protein targets for six leukemogenic tyrosine kinases governed by post-translational regulation. PLoS One 2012; 7: e38928.
14. Hickson I, Yan Z, Richardson CJ, Green SJ, Martin NMB, Orr AI et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004; 64: 9152-9159.
15. Old WM, Shabb JB, Houel S, Wang H, Couts KL, Yen C-y et al. Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 2009; 34: 115-131.
16. Li X, Brunton VG, Burgar HR, Wheldon LM, Heath JK. FRS2-dependent SRC activation is required for fibroblast growth factor receptor-induced phosphorylation of sprouty and suppression of ERK activity. J Cell Sci 2004; 117: 6007-6017.
17. Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase C8. Blood 2002; 100: 3741-3748.
18. Copland M, Hamilton A, Eirick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532-4539.
19. Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34(\+) CML cells. Blood 2007; 109: 4016-4019.
20. Hamilton A, Elrick L, Myssina S, Copland M, Jorgensen H, Melo JV et al. BCR-ABL activity and its response to drugs can be determined in CD34(\+) CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia 2006; 20: 1035-1039.
21. Woodcock SA, Rooney C, Liontos M, Connolly Y, Zoumpourlis V, Whetton AD et al. Src-induced disassembly of adherens junctions requires localized phosphorylation and degradation of the Rac activator Tiam1. Mol Cell 2009; 33: 639-653.
22. Whetton AD, Lu YN, Pierce A, Carney L, Spooncer E. Lysophospholipids synergistically promote primitive hematopoietic cell chemotaxis via a mechanism involving Vav 1. Blood 2003; 102: 2798-2802.
23. Pierce A, Unwin RD, Evans CA, Griffiths S, Carney L, Zhang L et al. Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases. Mol Cell Proteomics 2008; 7: 853-863.
24. Tartari CJ, Gunby RH, Coluccia AML, Sottocornola R, Cimbro B, Scapozza L et al. Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J Biol Chem 2008; 283: 3743-3750.
25. Siitonen T, Alaruikka P, Mantymaa P, Savolainen ER, Kavanagh TJ, Krejsa CM et al. Protection of acute myeloblastic leukemia cells against apoptotic cell death by high glutathione and gamma-glutamylcysteine synthetase levels during etoposide-induced oxidative stress. Ann Oncol 1999; 10: 1361-1367.
26. Griaud F, Williamson AJK, Taylor S, Potier DN, Spooncer E, Pierce A et al. BCR/ABL modulates protein phosphorylation associated with the etoposide-induced DNA damage response. J Proteomics 2012, e-pub ahead of print 15 June 2012; doi:10.1016/j.jprot.2012.06.003.
27. Cao C, Leng YM, Liu X, Yi YP, Li P, Kufe D. Catalase is regulated by ubiquitination and proteosornal degradation. Role of the c-Abl and Arg tyrosine kinases. Biochemistry 2003; 42: 10348-10353.
28. Li BJ, Wang XY, Rasheed N, Hu YY, Boast S, Ishii T et al. Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C delta. Genes Dev 2004; 18: 1824-1837.
29. Dittmann K, Mayer C, Kehlbach R, Rothmund M-C, Peter Rodemann H. Radiation-induced lipid peroxidation activates src kinase and triggers nuclear EGFR transport. Radiother Oncol 2009; 92: 379-382.
30. Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk DS et al. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1 alpha. Blood 1999; 94: 4233-4246.
31. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690-698.
32. Gioia R, Leroy C, Drullion C, Lagarde V, Etienne G, Dulucq S et al. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. Blood 2011; 118: 2211-2221.
33. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 108: 319-327.
34. Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463: 676-680.
35. Yalcin S, Marinkovic D, Mungamuri SK, Zhang X, Tong W, Sellers R et al. ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(/) mice. EMBO J 2010; 29: 4118-4131.
36. Saunders AE, Johnson P. Modulation of immune cell signalling by the leukocyte common tyrosine phosphatase, CD45. Cell Signal 2010; 22: 339-348.
37. Hermiston ML, Zikherman J, Zhu JW. CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells. Immunol Rev 2009; 228: 288-311.
38. Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005; 23: 879-894.
39. Whetton AD, Graham GJ. Homing and mobilization in the stem cell niche. Tr Cell Biol 1999; 9: 233-238.
40. Tabe Y, Jin L, Iwabuchi K, Wang RY, Ichikawa N, Miida T et al. Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts. Leukemia 2012; 26: 883-892.
41. Weisberg E, Azab AK, Manley PW, Kung AL, Christie AL, Bronson R et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 2012; 26: 985-990.